Hospira Inc., a Pfizer company, is recalling approximately 178,118 vials of Labetalol Hydrochloride Injection, USP (100 mg/20 mL), which is used to treat high blood pressure. The recall was initiated because of a defect where the glass at the rim of the vials may be cracked, though the damage is hidden by the stopper and seal. This affects both Hospira-branded and NOVAPLUS-branded vials distributed nationwide across the United States and Puerto Rico. Consumers should check their medication supply immediately and consult with their healthcare provider if they have been using these specific lots.
A cracked glass rim can compromise the sterile seal of the vial, potentially allowing bacteria or other contaminants to enter the medication. If contaminated medication is injected, it could lead to serious infections or other health complications.
Healthcare provider consultation and pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.